Researchers comparing structural variant detection using short- and long-read technologies said assembly-based methods can provide added value, despite missing certain CNVs.
The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.
Illumina said it plans to "vigorously defend" the deal and oppose the FTC, which previously helped scuttle Illumina's proposed acquisition of Pacific Biosciences.
The hybridization-based test may provide better detection of emerging COVID-19 variants of concern, due to a higher tolerance for probe mismatches than in PCR.
The deal to create a comprehensive genomic profiling test for Illumina's NextSeq 550Dx comes months after the instrument received regulatory approval in China.
The agreement, which provides an unsecured five-year revolving credit facility, includes an option for Illumina to take out additional loans of up to $250 million.
SUGAR-seq, a single-cell method developed by researchers in Australia, is a first step towards analyzing differences in glycosylation in various cell types.
Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.
